PI
Penumbra Inc (PEN)·Q2 2025 Earnings Summary
Executive Summary
- Q2 2025 delivered revenue of $339.5M (+13.4% YoY) and non-GAAP diluted EPS of $0.86; revenue and EPS both beat Wall Street consensus ($327.4M* revenue; $0.82* EPS), while gross margin was 66.0%, modestly below consensus (66.45%*) . Values retrieved from S&P Global.
- Management raised full-year revenue guidance to $1.355B–$1.370B (from $1.340B–$1.360B in Q1), maintained U.S. thrombectomy growth of 20–21%, and reiterated full-year gross and operating margin targets .
- U.S. thrombectomy remained the growth engine: $188.5M (+22.6% YoY), with U.S. VTE up 42% YoY on strong adoption of FLASH 2.0 and Lightning Bolt 12; embolization/access rose to $109.2M (+13.9% YoY), aided by the Ruby XL launch .
- Margin trajectory remains intact despite front-loaded commercial hiring and XL launch costs; management reiterated the path to 70%+ gross margin by end of 2026 and expects sequential margin expansion in 2H25 .
- Near-term catalysts: STORM-PE randomized trial results (fall), ongoing FDA process for Thunderbolt, and continued Ruby XL rollout; China headwinds showed signs of easing (small order placed after tariff pause) .
What Went Well and What Went Wrong
What Went Well
- Non-GAAP EPS and revenue both exceeded Street expectations; operating income of $40.8M (12.0% margin) and adjusted EBITDA of $61.4M (18.1% margin) demonstrated disciplined execution . Consensus: $0.82* EPS; $327.4M* revenue. Values retrieved from S&P Global.
- U.S. thrombectomy revenue grew 22.6% YoY to $188.5M, with U.S. VTE +42% YoY; CEO: “We treated more VTE patients in the quarter than in any prior period” .
- Commercial and product progress: Ruby XL FDA-cleared and launched; over 50 embolization reps and 40 vascular clinical specialists added to sharpen focus across thrombectomy and embolization .
What Went Wrong
- Gross margin of 66.0% was slightly below consensus (66.45%*) and down sequentially versus Q1 (66.6%), reflecting XL launch investments and higher international mix; management expects sequential expansion in 2H25 . Values retrieved from S&P Global.
- International thrombectomy declined 16.2% YoY, primarily due to continued China weakness; CFO noted headwinds should ease in 2H25 .
- Street flagged margin pressure from front-loaded hiring and potential near-term mix variability; CFO confirmed no impact to gross margin from commercial hiring but acknowledged timing/mix effects and maintained full-year margin guidance .
Financial Results
Summary vs prior quarters and YoY/Sequential
Q2 2025 vs Wall Street Consensus
Values retrieved from S&P Global.
Segment Breakdown – Q2 2025
KPIs – Q2 2025
Guidance Changes
Earnings Call Themes & Trends
Management Commentary
- “Gross margin of 66% was in line with our prior announced expectation as we executed on our planned accelerated Ruby XL inventory build… we remain on track… to achieve a gross margin profile of over 70% by the end of 2026.” — CEO .
- “Revenue… $339.5 million… U.S. thrombectomy… increased 22.6%… led by 42% year-over-year growth in our U.S. VTE franchise.” — CEO .
- “We have added over 50 embolization sales reps and over 40 vascular clinical specialists… [enabling] a team solely focused on our thrombectomy business, as well as a separate team focused on launching Ruby XL.” — CEO .
- “We ended the second quarter… with cash, cash equivalents, and marketable securities… $424.6 million and no debt… driven by strong operating profitability.” — CFO .
- “Due to our performance… we are increasing… total revenue to… $1,355 million–$1,370 million… maintain U.S. thrombectomy growth of 20%–21%… maintain… gross margin and operating margin.” — EVP Strategy .
Q&A Highlights
- Margins/mix: Gross margin variability tied to XL launch/mix; commercial hiring does not impact gross margin; full-year margin guidance maintained despite front-loaded hiring .
- U.S. thrombectomy guide conservatism: Despite 24% 1H growth, management kept 20–21% full-year guide to avoid “getting ahead of ourselves” .
- China/international: Small China order after tariff pause; expectation of easing headwinds and return to intl growth in 2H25 .
- Thunderbolt timing: Active FDA review; management reiterated strong enthusiasm but refrained from timing commentary .
- Market share: Management indicated >50% share in DVT and meaningful gains in PE; continued share capture in neuro despite slower market growth .
Estimates Context
- Q2 2025 comparison: Revenue $339.5M vs $327.4M*; Primary EPS $0.86 vs $0.82*; Gross margin 66.0% vs 66.45%* . Values retrieved from S&P Global.
- Implication: Street likely raises FY revenue outlook incrementally following the guide raise; margin estimates may be fine-tuned for mix/sequential cadence given XL and international dynamics .
Key Takeaways for Investors
- Revenue/EPS beat with guide raise should support near-term positive sentiment; slight gross margin miss viewed as mix/launch-timing rather than structural .
- U.S. VTE momentum remains robust; continued CAVT adoption is driving share gains and higher patient volumes — a core medium-term growth pillar .
- Ruby XL launch broadens embolization TAM and is margin-accretive; the sales force split should enhance focus and execution across both franchises .
- Thunderbolt is a key neuro catalyst; near-term approval timing is uncertain, but Red 72 Silver Label is positioning accounts ahead of launch .
- International normalization (especially China) could provide incremental upside in 2H25 if headwinds ease as guided .
- Margin trajectory to 70%+ by end-2026 remains intact; expect sequential expansion in 2H25 as mix/productivity improves .
- Near-term trading setup: Positive on beats and guide raise; watch for STORM-PE data (fall) and any Thunderbolt regulatory updates as stock-moving catalysts .